

## White Paper: Bridging the gap between surveillance data and antimicrobial stewardship in the animal sector—practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks

Monica Compri<sup>1†</sup>, Rodolphe Mader<sup>2\*†</sup>, Elena Mazzolini<sup>3†</sup>, Giulia de Angelis<sup>4,5</sup>, Nico T. Mutters<sup>6</sup>, Nithya Babu Rajendran<sup>7,8</sup>, Liliana Galia<sup>1</sup>, Evelina Tacconelli<sup>1,7,8</sup> and Remco Schrijver<sup>9</sup> on behalf of the ARCH working group‡

<sup>1</sup>Infectious Diseases Section, Department of Diagnostics and Public Health, University of Verona, Verona, Italy; <sup>2</sup>University of Lyon, French Agency for Food, Environmental and Occupational Health and Safety (ANSES), Laboratory of Lyon, Antimicrobial Resistance and Bacterial Virulence Unit, Lyon, France; <sup>3</sup>Department of Epidemiology, Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro, Padua, Italy; <sup>4</sup>Dipartimento di Scienze Biotechnologiche di base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy; <sup>5</sup>Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; <sup>6</sup>Institute for Hygiene and Public Health, Bonn University Hospital, Bonn, Germany; <sup>7</sup>Infectious Diseases, Department of Internal Medicine I, Tübingen University Hospital, Tübingen, Germany; <sup>8</sup>German Centre for Infection Research (DZIF), Clinical Research Unit for healthcare associated infections, Tübingen, Germany; <sup>9</sup>VetEffect, Bilthoven, The Netherlands

\*Corresponding author. E-mail: rodolphe.mader@anses.fr

†Equally contributing first authors.

‡Members are listed in the Acknowledgements section.

**Background:** The JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks have joined efforts to formulate a set of target actions to link the surveillance of antimicrobial usage (AMU) and antimicrobial resistance (AMR) with antimicrobial stewardship (AMS) activities in four different settings. This White Paper focuses on the veterinary setting and embraces the One Health approach.

**Methods:** A review of the literature was carried out addressing research questions in three areas: AMS leadership and accountability; AMU surveillance and AMS; and AMR surveillance and AMS. Consensus on target actions was reached through a RAND-modified Delphi process involving over 40 experts in infectious diseases, clinical microbiology, AMS, veterinary medicine and public health, from 18 countries.

**Results/discussion:** Forty-six target actions were developed and qualified as essential or desirable. Essential actions included the setup of AMS teams in all veterinary settings, building government-supported AMS programmes and following specific requirements on the production, collection and communication of AMU and AMR data. Activities of AMS teams should be tailored to the local situation and capacities, and be linked to local or national surveillance systems and infection control programmes. Several research priorities were also identified, such as the need to develop more clinical breakpoints in veterinary medicine.

**Conclusions:** This White Paper offers a practical tool to veterinary practitioners and policy makers to improve AMS in the One Health approach, thanks to surveillance data generated in the veterinary setting. This work may also be useful to medical doctors wishing to better understand the specificities of the veterinary setting and facilitate cross-sectoral collaborations.

### Introduction

Veterinary and human medicine share the responsibility of preserving the efficacy of antibiotics and preventing the spread of antimicrobial resistance (AMR). To a large extent, the antimicrobial drugs (or classes) that are used in animals are the same as those in human settings<sup>1–3</sup> and resistant bacteria can be transferred

between animals, the environment and humans through different routes of transmission.<sup>1–4</sup> This renders AMR a One Health issue requiring multi-sectoral collaborations.<sup>4–6</sup>

To prevent the spread of AMR, antimicrobial stewardship (AMS) should be developed collectively in all settings where antimicrobials are used as ‘a coherent set of actions which promote using

antimicrobials responsibly.<sup>7</sup> Indeed, AMS interventions in one setting can have a positive impact in another,<sup>5</sup> and this is particularly the case for the animal sector, where interventions are commonly carried out with a public health perspective.<sup>1,8,9</sup> However, the specificities of each setting should always be carefully taken into account when devising an AMS programme.<sup>10–14</sup>

The veterinary sector is highly heterogeneous. Veterinarians can work as independent private practitioners (acting alone) or be organized in veterinary clinics or hospitals with multiple staff, that can be owned by individuals or by national or multinational veterinary healthcare enterprises. Veterinarians deal with different animal species that include companion animals, food-producing animals and, although less commonly, wild animals. Veterinarians can prescribe and dispense antimicrobials for various purposes, i.e. treatment, metaphylaxis (administration of a drug to a group of clinically healthy animals in contact with diseased animals),<sup>15</sup> prevention and growth promotion (where allowed) for individual animals or groups of animals.<sup>15–17</sup> Access to antimicrobials also differs greatly between countries<sup>18–20</sup> and is sometimes readily available without any prescription to farmers or pet owners,<sup>21–23</sup> leading to further difficulties in controlling antimicrobial usage (AMU).

Monitoring AMU is important to quantitatively assess the performance of a National Action Plan (NAP) in reducing the overall use of antimicrobials, to target interventions in animal species to prevent using unjustified amounts of antimicrobials and to check that the veterinary use of antimicrobials critically important for human health is minimized.<sup>24–26</sup> When carried out at the level of prescription, it can become a benchmarking tool where prescribers, sellers or farmers can compare their antimicrobial usage against a regional average or a particular food-production sector.<sup>27–30</sup> Although such systems may require specific legislation, they can be useful to reduce AMU, especially when linked with incentives for lower usage or targeted interventions to high antimicrobial users.<sup>31</sup> It is noteworthy that NAPs on AMR, although recommended by the World Health Organization (WHO) and WHO Member States, are not legally binding. This limits the power of NAPs as a governance tool.<sup>32</sup>

In addition, it is key to monitor AMR in animal bacterial pathogens<sup>33–35</sup> to help veterinarians and farmers use antimicrobials more prudently, follow AMR trends and advise action at national or more local levels. Moreover, showing AMS teams and other actors in animal health that their efforts succeed not only in decreasing AMU but also AMR is necessary to maintain their commitment. In the One Health approach it is also paramount to monitor AMR in zoonotic and commensal bacteria<sup>36,37</sup> from healthy animals to assess the risk of transmission to humans through the food chain (or by direct contact), as this can lead to better risk management interventions.<sup>38</sup> Of note, commensal bacteria are a useful indicator for the comparison of AMR rates over time and between different animal species, countries or farms.

Despite a general call to develop monitoring systems that are able to provide relevant, accurate and complete data to drive AMS programmes in all settings, including the animal sector, many gaps still remain, along with many harmonization challenges. For example, only fragmentary data on AMU and AMR are available for companion and aquatic animals.<sup>39–42</sup> Regarding AMR data, most of the available information comes from healthy terrestrial food-producing animals and relatively few multi-annual

programmes are in place for the monitoring of AMR in animal pathogens.<sup>43–45</sup>

The complexity of the veterinary setting (including its interconnections with the human sector, the varying purposes of surveillance systems<sup>26,46,47</sup> and the non-homogeneous availability of surveillance data and resources around the world<sup>48,49</sup>) make many activities difficult to standardize. Thus, practical details are not available for many AMS activities, and indications on how surveillance data should intertwine with AMS interventions are lacking.

The JPIAMR ARCH<sup>50</sup> and COMBACTE-MAGNET EPI-Net<sup>51</sup> networks have come together for the shared goal of implementing a framework of actions to facilitate antibiotic policy interventions and foster use of surveillance data on AMR and consumption and implementation of AMS activities in human and animal health.

In this regard, the ARCH and COMBACTE-MAGNET EPI-Net international expert panel is focusing on four settings: hospital, outpatient, long-term care facility, and veterinary. The efforts involve three areas: (i) AMS leadership and accountability; (ii) AMU and AMS; and (iii) AMR and AMS, all considering the feasibility of the actions and the One Health approach.

This White Paper focuses on the veterinary sector and targets veterinarians, policymakers and other actors in animal and human health who are involved in AMS activities. The proposed guidance is intended as a practical tool regarding the production and use of AMU and AMR data to plan and implement AMS programmes in line with the One Health approach and applicable in different veterinary contexts, including resource-limited countries. Dissemination to the intended audience will be ensured by the networks involved in the JPIAMR ARCH project as listed in Table 1 of the first paper in this series.<sup>52</sup> Checklist formats of the target actions are downloadable from the ARCH website.<sup>50</sup> These checklists can be used by health professionals and policymakers to establish and/or monitor stewardship activities.

## Methods

Adopting a One Health approach, the present project was planned to develop expert consensus considering the literature and guidance on AMS and surveillance. A first draft of targets and a RAND-modified Delphi process were used for validation of targets (protocol on ARCH website).<sup>50</sup> The process involved development of key research questions arising from a systematic review on surveillance reporting of AMR that was previously developed (EPI-Net COACH project)<sup>53</sup> and adapted to a veterinary setting (Table 1); a narrative review of the available evidence was performed, and a first draft of targets was provided to the experts in a web-based survey. Agreement was expressed on a nine-point Likert scale. A 2 day face-to-face meeting took place at the end of October 2019. A literature search of relevant publications in English, published in the last 10 years, was carried out using MEDLINE (National Library of Medicine, Bethesda, MD, USA) using a combination of the following terms: antimicrobial\*, consumption, animal\*, veterinary, antimicrobial drug resistance, surveillance. More details are available in the first paper in this series.<sup>52</sup>

During the meeting, the experts were presented with a summary of the available evidence and the results of the online survey. The entire set of targets was reviewed and discussed. Following the meeting, a core team (M.C., E.M., R.M., R.S.) of the veterinary working group performed a further revision and fine-tuning of the list of targets, which was then approved by the entire panel in an additional consultation. To cover all different veterinary features and related interconnections with human health, different

**Table 1.** Key questions for the veterinary setting**1. Leadership commitment, accountability and antimicrobial stewardship team**

- Participants in the antimicrobial stewardship team
- Targets of antimicrobial stewardship (e.g. is antimicrobial stewardship targeted to diseased animals?)
- Institutional support for organization and management of antimicrobial stewardship programmes: legal framework
- Institutional support for organization and management of antimicrobial stewardship programmes: staffing personnel

**2. Antimicrobial usage and antimicrobial stewardship**

- Which antibiotics should be monitored?
- Which metrics should be employed for monitoring antimicrobial usage?
- Should the surveillance specify the purpose of antimicrobial usage?
- Which criteria for reporting and time interval should be used?
- Who should be the end user of the report?
- Should a restrictive policy be adopted?
- Should a ranking for antibiotic use be adopted?

**3. Antimicrobial resistance and antimicrobial stewardship**

- Which criteria are needed to target resistant pathogens?
- How should resistance be monitored?
- Which prevalence data and selective monitoring screening should be considered?
- Which criteria for reporting and time interval should be used?
- Which criteria should be applied to stratify the results?
- Who should be the end user of the report?
- Should the report set specific thresholds for establishing empirical therapy and surgical prophylaxis?
- Which criteria should be used to drive selective reporting of antibiograms?

settings (farms, veterinary clinics, etc.) and animal populations (companion and food-producing animals, including aquatic animals) were considered. Recommendations, state of the art, and original approaches were evaluated by focusing on feasibility and adaptability to different economic and veterinary contexts to compile a list of ‘essential’ and ‘desirable’ targets. Targets were recognized as ‘essential’ when widely practicable if not already broadly accomplished, and ‘desirable’ in the case of limited feasibility or having a resource-intensive nature. Topics for which more evidence was required in order to draw up recommendations were added as priority topics for further research.

Over 40 experts from 18 countries and representing 30 networks developed the protocol, contributed to reaching a consensus and approved the final list of indications (see first paper in this series).<sup>52</sup>

## Results

A total of 49 guidance documents (23 international and 26 national documents) and 45 articles including systematic reviews, studies and expert opinions were included for the full evidence appraisal.<sup>1,3,4,8–17,19,20,22,24,27,28,31,33,34,36–38,40,41,46–48,54–117</sup> International and national guidelines, practical guides or tools, surveillance reports and systematic reviews provided most of the evidence. The majority of the documents (71/94, 76%) were from high-income countries (Europe, North America, Australia and New Zealand).

For two research questions (‘Should the report set specific thresholds for establishing empirical therapy and surgical prophylaxis?’ and ‘Which criteria should be used to drive selective reporting of antibiograms?’), the information did not allow drafting of specific targets, and thus these topics were addressed as future research areas.

An initial set of 65 targets was developed based on retrieved documents and assessed by eight experts in the field of human and veterinary medicine through the online survey. Consensus was reached on 54 targets, and additional comments were provided for most of them.

Eleven targets, where the agreement was not reached after first consultation, were discussed in the meeting. Main topics of discussion revolved around: (i) the organization of AMS considering participants and roles of the AMS team and institutional support; (ii) bacterial species to monitor considering human and animal health; and (iii) how to deal with the lack of clinical breakpoints to implement AMS activities. Nine targets were deleted during the meeting. All other targets were reconsidered and proposed for rephrasing (some were merged or split) or additional evaluation following the suggestions of the panel.

After the meeting, a list of 46 revised targets (25 essential and 21 desirable) was drafted by the core group and approved by the entire expert panel. Tables 2–4, respectively, list the recommended targets for AMS leadership and accountability, AMU and AMS, and AMR and AMS. Tables 5–8 refer to the statements of Tables 2–4.

## Discussion

Interestingly, AMS leadership and accountability in the animal sector was one of the main topics of discussion during the meeting. This may reveal that more efforts have been made to develop AMR and AMU surveillance systems in comparison with efforts for structuring and guiding AMS activities in veterinary practices. Although preliminary agreement was reached for all proposed targets but one within the online survey, comments and suggestions were provided during the consultations that required further evaluation. This is likely due to the broad heterogeneity of the veterinary sector considering animal species, animal populations (food-producing animals including aquaculture and companion animals) and the various contexts where animal healthcare is provided (farms, small veterinary clinics, large hospitals, etc.).

The expert group is aware that the desirable composition of the AMS team described is often not feasible, but the action point aims to define the best options when establishing an AMS team. Very often, the team may be composed of only a farmer and his/her veterinarian, working together to rationalize AMU. However, for large clinics and farming industries that have their own pharmacies and laboratories, the composition of the AMS team could come close to what is recommended.<sup>10,12,54,99,100</sup>

Debates also arose regarding the role of animal owners. Although pet owners are responsible for the administration of antimicrobial treatments to their animals, it is not realistic to include them in AMS teams. On the other hand, farmers (and also breeders of horses or companion animals), who are professional animal keepers, do bear responsibility for the prudent use of antibiotics<sup>11,55,56</sup> and have a major role to play in AMS.<sup>4,19,90</sup> Still, pet owners should be targeted by educational activities to foster the

**Table 2.** Leadership commitment, accountability and antimicrobial stewardship team**Antimicrobial stewardship programme and team**

## 1.1. Essential

Antimicrobial stewardship programmes should be in place in every setting where antimicrobials are used to treat food-producing or companion animals, with targets and interventions tailored to the local situation and linked to local and national surveillance systems and infection control programmes.

## 1.2. Essential

Antimicrobial stewardship programmes should be defined, planned, implemented and evaluated by a dedicated and competent team. This team should be tailored, depending on the animal species and production type, to the local context and availability of resources and personnel.

## 1.3. Desirable

The team should include a veterinarian competent in antimicrobial stewardship and representatives of all professionals involved in animal care (para-veterinarians, veterinary nurses, farmers, veterinary pharmacists, microbiologists from diagnostic laboratories, etc.) in a collaborative approach, under the leadership of the veterinarian. This team should seek professional advice from additional experts when needed to adequately fulfil their antimicrobial stewardship activities.

**Institutional support for organization and management of antimicrobial stewardship programmes**

## 1.4. Essential

Antimicrobial stewardship programmes should be supported at the governmental level through frameworks such as the National Action Plan in line with relevant international standards. The National Action Plan should include regulatory decisions to restrict the usage of antimicrobials in food-producing and companion animals, set specific reduction targets for antimicrobial usage and establish monitoring systems for antimicrobial usage and antimicrobial resistance.

## 1.5. Desirable

Surveillance data on antimicrobial usage and antimicrobial resistance should be made freely available to local antimicrobial stewardship teams, as well as to all other professionals working in animal, human or environmental health.

## 1.6. Desirable

Voluntary approaches to improve antimicrobial stewardship and surveillance in the animal sector should be encouraged, e.g. when the farming industry adopts its own measures to increase biosecurity, infection control and reduce antimicrobial usage.

appropriate use of antimicrobials, along with veterinarians, farmers and other actors in animal health.<sup>13,58,101,118</sup>

AMS should be implemented from the local to the global level, spanning human health, animal health and the environment.<sup>2,12,58,119</sup> Therefore, even in the veterinary setting, AMS should be devised and supported at a higher level, especially by governments and industry<sup>57,59,60,110</sup> in the form of NAPs and good practice charters. These should recommend measures to reduce AMR and provide guidance to AMS teams in the field. Setting targets for reduction,<sup>61,62</sup> as well as restricting AMU in animals,<sup>9,41,63,104</sup> has been shown to be very effective in several countries.<sup>120</sup> To foster AMS, governments should support AMU and AMR monitoring systems.<sup>39,58,59,113</sup> More broadly, institutional support is crucial in terms of communication and progress reporting, and to ensure transparency of information on both AMU and AMR.

There must also be support for any voluntary approaches, provided they are in line with government policy.<sup>60</sup> For example, industry initiatives to restrict the use of some antimicrobial classes have been shown to be efficient at reducing resistance rates<sup>120,121</sup> and should be encouraged. The development of quality policies in veterinary clinics with a dedicated component on AMS activities should also be promoted.

The design of AMU or AMR monitoring systems should depend on their objectives, existing contexts and capacities, and be consistent with national guidelines, if any.<sup>14,48</sup> However, existing

policies on access and use of antimicrobials may differ substantially among countries.<sup>19,21,22,42,56</sup> A veterinary prescription may or may not be compulsory, impairing the availability of herd-level benchmarking. Additionally, the lack of national legislations/regulations still permits some countries to use antimicrobials as growth promoters,<sup>17,18,122</sup> although this practice is strongly discouraged by international organizations, including the WHO,<sup>1</sup> the World Organisation for Animal Health (OIE),<sup>123</sup> and European legislation.<sup>15</sup> To help in their design, rankings of antimicrobials from international organizations can be used (WHO, OIE, EMA), in particular categorizations that consider the risk that animal usage of antimicrobials may pose to public health in the One Health approach.<sup>9</sup>

The consensus between experts regarding AMU statements was easily achieved, likely due to the numerous efforts that have already been established in this field, namely in the framework of the European Surveillance of Veterinary Antimicrobial Consumption (ESVAC). If usage of all antimicrobials cannot be monitored, as would be desirable,<sup>64</sup> targeting specific animal species and antimicrobial classes is preferred. A major issue is that AMU data can be collected in different ways.<sup>26,28,40,92</sup> When possible, prescriptions and, even better, animal administration data should be collected from veterinarians and farmers as these provide the most accurate data on AMU (when properly recorded) and allow benchmarking.<sup>27,36,62,112</sup> If this is not possible, sales data may be collected from pharmaceutical companies.<sup>26,65,66</sup>

**Table 3.** Antimicrobial usage and antimicrobial stewardship**Which types of antimicrobial usage, animal species and antimicrobials should be monitored?**

## 2.1. Essential

Antimicrobial usage should be monitored whatever the purpose of antimicrobial administration. This includes growth promotion, a practice that should be discouraged.

## 2.2. Essential

Antimicrobial usage should be monitored in food-producing (including aquatic) and companion animals.

## 2.3. Desirable

Antimicrobial usage should be monitored for all animals for which antimicrobials are authorized in a country.

## 2.4. Essential

If national monitoring of antimicrobial usage including all antimicrobials is not feasible, a risk-based approach should be promoted to target monitoring to the most relevant antibiotics for animal and/or human health and only within the most important animal species in a country or region.

## 2.5. Essential

The choice of antimicrobials to be monitored should be guided by the World Health Organization (WHO) ranking of critically important antimicrobials, by the World Organisation for Animal Health (OIE) list of antimicrobial agents of veterinary importance and by specific rankings of risk to public health from antimicrobial resistance due to the use of antimicrobials in veterinary medicine (example in Table 5).

**Which metrics should be employed?**

## 2.6. Essential

Antimicrobial usage should be monitored at least at the country level, for all or selected combinations of animal species and antimicrobials.

## 2.7. Desirable

Antimicrobial usage should be monitored at the level of each prescription, sale or animal administration, such as veterinary clinics, pharmacies and farms, for all or selected combinations of animal species and antimicrobials.

## 2.8. Essential

Sales data are the minimum that should be provided for all or selected combinations of animal species and antimicrobials, in kilograms of active ingredient for all animals and in milligrams per population correction unit (PCU) for food-producing animals.

## 2.9. Desirable

When data are available on prescriptions, sales and animal administration, the amount of overall usage should be standardized according to animal production and antimicrobial daily doses or antimicrobial treatment course.

**Which data and stratification criteria should be adopted?**

## 2.10. Desirable

Additional data should be collected as part of an antimicrobial usage monitoring such as age, production type, route of administration or treatment type (therapy, metaphylaxis, prophylaxis or growth promotion). The data analysis should be stratified according to these additional data.

**Which criteria for time interval and reporting should be used?**

## 2.11. Essential

Antimicrobial usage data should be reported annually.

## 2.12. Essential

Surveillance data on antimicrobial usage should be reported at the national level.

## 2.13. Desirable

Surveillance data on antimicrobial usage should be reported at the local level.

## 2.14. Essential

All methods used to provide antimicrobial usage data should be clearly described.

## 2.15. Desirable

Antimicrobial usage and antimicrobial resistance data in the animal sector should be analysed, interpreted and reported in the same report. In the One Health approach, this report should also include data on antimicrobial usage and antimicrobial resistance from the human sector.

## 2.16. Desirable

The report should include an English version to foster easier sharing of information between countries.

**Who should be the end user of the report?**

## 2.17. Essential

The end users of reports on antimicrobial usage should be antimicrobial stewardship teams and all other stakeholders in animal, human and environmental health at the local, institutional or industry level.

## 2.18. Desirable

The report should be freely available online to anyone and include a summary that is understandable for the general public.

**Table 4.** Antimicrobial resistance and antimicrobial stewardship**Which animal species and resistant bacteria should be targeted?**

## 3.1. Essential

Antimicrobial resistance should be monitored in food-producing (including aquatic) and companion animals.

## 3.2. Essential

The target resistant bacteria should be animal pathogens, but also zoonotic pathogens and commensals in the One Health approach.

## 3.3. Essential

OIE criteria should be followed for the choice of animal pathogenic bacteria to monitor (Table 6). Examples from OIE in terrestrial food-producing animals are provided in Table 7.

## 3.4. Desirable

In companion animals, target pathogenic bacteria may include methicillin-resistant *Staphylococcus aureus* (MRSA) and methicillin-resistant *Staphylococcus pseudintermedius* from skin samples and *Escherichia coli* from urine samples, considering their importance for animal health and the zoonotic potential of MRSA.

## 3.5. Essential

Selection criteria for the foodborne zoonotic and commensal bacteria to include in an antimicrobial resistance integrated surveillance programme should depend on public health priorities, antimicrobial use practices and the estimates of the burden of foodborne illnesses, as stated by WHO (Table 8).

## 3.6. Essential

The choice of antimicrobials to monitor should be guided by the WHO ranking of critically important antimicrobials, by the OIE list of antimicrobial agents of veterinary importance and by specific rankings of risk to public health from antimicrobial resistance due to the use of antimicrobials in veterinary medicine (example in Table 5).

**How should resistance be monitored?**

## 3.7. Essential

For animal pathogenic bacteria, samples should originate from diseased or dead animals.

## 3.8. Essential

For indicator and zoonotic bacteria from food-producing animals, samples should be taken from healthy animals of defined age.

## 3.9. Essential

Standardized and internationally recognized antimicrobial susceptibility testing methods should be used.

## 3.10. Desirable

To support field antimicrobial stewardship teams and provide recommendations for antimicrobial therapy in veterinary settings, clinical breakpoints should be used to interpret antimicrobial susceptibility testing results. If not available, epidemiological cut-off values may be used. When the objective is to detect decreased susceptibility (i.e. to display a microbiological resistance), epidemiological cut-offs should be used.

## 3.11. Desirable

Quantitative data (MICs or inhibition zone diameters) should be collected rather than interpreted data (susceptible/intermediate/resistance or wild type/non-wild type).

## 3.12. Desirable

Specific monitoring schemes may be performed in healthy animals and food thereof using selective media, e.g. to detect the presence ESBL/AmpC, carbapenemase-producing, colistin-resistant Enterobacterales, MRSA or vancomycin-resistant enterococci to assess public health risk.

## 3.13. Desirable

Resistance mechanisms should be characterized at the molecular level, e.g. using the polymerase chain reaction, sequencing or whole-genome sequencing for colistin-resistant ESBL/AmpC- and carbapenemase-producing Enterobacterales.

**Which data and stratification criteria should be adopted?**

## 3.14. Desirable

Additional data should be collected as part of antimicrobial resistance monitoring, such as age, production type and specimen, and if the antimicrobial susceptibility testing was requested due to a previous antimicrobial treatment failure. The analysis should be stratified according to these additional data.

Continued

**Table 4.** Continued**Which criteria for time interval and reporting should be used?**

## 3.15. Essential

The time interval for reporting resistance data should be annual, but emerging resistances should be reported in as timely a fashion as possible.

## 3.16. Essential

Surveillance data on antimicrobial resistance should be reported at the national level.

## 3.17. Desirable

Surveillance data on antimicrobial resistance should be reported at the local level.

## 3.18. Essential

All standards and guidance documents used for bacterial isolation, bacterial identification and antimicrobial susceptibility testing should be clearly described.

## 3.19. Desirable

Antimicrobial usage and antimicrobial resistance data in the animal sector should be analysed, interpreted and reported in the same report. In the One Health approach, this report should also include data on antimicrobial usage and antimicrobial resistance from the human sector.

## 3.20. Desirable

The report should include an English version to foster easier sharing of information between countries.

**Who should be the end users of the report?**

## 3.21. Essential

The end users of reports on antimicrobial resistance should be antimicrobial stewardship teams and all other stakeholders in animal, human and environmental health at the local, institutional or industry level.

## 3.22. Desirable

The report should be freely available online to anyone and include a summary that is understandable for the general public.

However, such data have a number of limitations, such as lack of information on the animal species, categories (adult versus young animal) to be treated and scope of treatments.

Regarding the monitoring of AMR, the online survey highlighted several areas of only partial agreement, such as the bacteria to be monitored. This is likely due to the complexity of AMR monitoring in the animal sector, as both animal and public health need to be considered. The differences in design possibilities for AMU also apply to the monitoring of AMR,<sup>34,35,46,67,124</sup> especially since it should be done for animal bacterial pathogens to help in the development of empirical therapy recommendations in the veterinary setting,<sup>10,34,47,49</sup> and for zoonotic and commensal bacteria in the One Health approach.<sup>35,36,55,68,97</sup> This leads to very different sampling schemes: passive monitoring in diseased animals for animal pathogens and active monitoring in healthy animals for commensal and zoonotic bacteria. Monitoring systems may rely on phenotypic identification of resistance, but molecular identification of AMR determinants brings more accurate insights into the epidemiology of resistance genes,<sup>36,48,58,69</sup> especially between the animal and human sectors, and can generate better risk-management measures.

A specific challenge that applies to the translation of AMR surveillance data into AMS actions is the lack of clinical breakpoints to interpret antimicrobial susceptibility testing (AST) results for many combinations of animal species, bacterial species and clinical form. The large majority of existing breakpoints were produced by the CLSI.<sup>125</sup> In 2019, the Veterinary Committee on Antimicrobial Susceptibility Testing (VetCAST) of the EUCAST proposed its first

clinical breakpoints.<sup>126</sup> However, developing clinical breakpoints is a long and difficult process, and it is unlikely that many of the missing ones will be determined in the short term. When no breakpoint is available, epidemiological cut-offs (ECOFFs) can be used as an alternative.<sup>36,108,114</sup> However, ECOFFs detect decreased susceptibilities and, as such, are not proper indicators of clinical resistance.<sup>46,115</sup> When using ECOFFs instead of clinical breakpoints, resistance rates can be overestimated, so one should be cautious when providing treatment recommendations based on them.<sup>46</sup> Indeed, using ECOFFs must not lead to wrongly recommending the prescription of critically important antimicrobials when older drugs remain clinically efficient. Because interpretative criteria, either clinical breakpoints or ECOFFs, can change over time, it is important to collect and report on quantitative data (inhibition diameters or MICs) to enable the recalculation of resistance rates in historical data and still be able to analyse trends.<sup>33,36,46,69,115</sup>

To ensure that AMR and AMU monitoring systems serve AMS in the One Health approach, it is key to report data jointly with those of AMU and AMR in other sectors, especially the human one.<sup>36,48,60</sup> This prevents the provision of a fragmented picture of the AMR situation and facilitates a reciprocal understanding between actors that need to collaborate to improve AMS. However, cross-sectoral data analysis of AMU and AMR data is complex and requires prudent interpretation. This is why experts should always seek to summarize the results in a format that is understandable by all stakeholders in animal, public and environmental health, as well as by the general public.<sup>48</sup>

**Table 5.** Categorization of antimicrobials considering the risk to public health from their usage in veterinary medicine due to antimicrobial resistance, by the Antimicrobial Advice Ad Hoc Expert Group (AMEG) from the European Medicines Agency (EMA)<sup>9</sup>

Category	List of drugs
Category A 'Avoid'	<ul style="list-style-type: none"> <li>• Aminopenicillins</li> <li>• Carbapenems</li> <li>• Other cephalosporins (other than 1st, 2nd, 3rd and 4th generation) and penems (ATC code J01DI), including combinations of 3rd-generation cephalosporins with <math>\beta</math>-lactamase inhibitors</li> <li>• Glycopeptides</li> <li>• Glycylcyclines</li> <li>• Ketolides</li> <li>• Lipopeptides</li> <li>• Monobactams</li> <li>• Oxazolidinones</li> <li>• Penicillins (carboxypenicillins and ureidopenicillins, including combinations with <math>\beta</math>-lactamase inhibitors)</li> <li>• Phosphonic acid derivatives</li> <li>• Pseudomonic acid</li> <li>• Rifamycins (except rifaximin)</li> <li>• Riminofenazines</li> <li>• Streptogramins</li> <li>• Sulfones</li> <li>• Drugs used solely to treat tuberculosis or other mycobacterial diseases</li> <li>• Substances newly authorized in human medicine following publication of the AMEG categorization</li> </ul>
Category B 'Restrict'	<ul style="list-style-type: none"> <li>• 3rd- and 4th-generation cephalosporins, except combinations with <math>\beta</math>-lactamase inhibitors</li> <li>• Polymyxins</li> <li>• Quinolones (fluoroquinolones and other quinolones)</li> </ul>
Category C 'Caution'	<ul style="list-style-type: none"> <li>• Aminoglycosides (except spectinomycin)</li> <li>• Aminopenicillins in combination with <math>\beta</math>-lactamase inhibitors</li> <li>• Amphenicols</li> <li>• 1st- and 2nd-generation cephalosporins and cephamycins</li> <li>• Macrolides (not including ketolides)</li> <li>• Lincosamides</li> <li>• Pleuromutilins</li> <li>• Rifamycins (rifaximin only)</li> </ul>
Category D 'Prudent'	<ul style="list-style-type: none"> <li>• Aminopenicillins without <math>\beta</math>-lactamase inhibitors</li> <li>• Cyclic polypeptides</li> <li>• Nitrofurans derivatives</li> <li>• Nitroimidazoles</li> <li>• Penicillins (antistaphylococcal penicillins and natural penicillins)</li> <li>• Aminoglycosides (spectinomycin only)</li> <li>• Steroid antibacterials</li> <li>• Sulphonamides, dihydrofolate reductase inhibitors and combinations</li> <li>• Tetracyclines</li> </ul>

Further topics were explored and addressed as research areas during consultations. Although planning dedicated time and allocating specific measures for AMS teams are essential for AMS activities, detailed information on the minimum requirements for personnel according to the tasks of AMS programmes are lacking in the literature. Additionally, the lack of clinical breakpoints for many antimicrobials for many animal species remains an important limitation for the interpretation of AST and to guide prudent use of antimicrobials. This represents the main issue that must be addressed to improve AMS activities. Due to the lack of available

documents retrieved for two key questions and following the numerous discussions among the panel, additional topics were considered as important future research areas that should be investigated and could complement the current checklist. The main research priorities are summarized in Table 9.

To our knowledge, this is the first time that a consensus from an international group of veterinary and medical experts has been reached in the veterinary setting regarding AMS leadership and accountability, as well as on the AMU and AMR information that monitoring systems should provide in the animal sector to support AMS



**Table 6.** OIE criteria to be considered in the choice of animal bacterial pathogens for inclusion in an AMR monitoring programme<sup>a</sup>

- Impact on animal health and welfare
- Implication of antimicrobial resistance of the animal bacterial pathogen on therapeutic options in veterinary practice
- Impact on food security and on production (economic importance of associated diseases)
- Bacterial diseases responsible for the majority of veterinary antimicrobial usage (stratified by usage of different classes or their importance)
- Existence of validated susceptibility testing methodologies for the bacterial pathogen
- Existence of quality assurance programmes or other pathogen-reduction options that are non-antimicrobial, such as vaccines and Good Agricultural Practices

<sup>a</sup>Adapted from Table 2 of reference 33.

**Table 7.** OIE example of bacterial pathogens in terrestrial food-producing animals to include in an AMR monitoring programme<sup>a</sup>

Species	Respiratory pathogens	Enteric pathogens	Other pathogens
Cattle	<i>Pasteurella multocida</i> , <i>Mannheimia haemolytica</i>	<i>Escherichia coli</i> , <i>Salmonella</i> spp.	Udder pathogens <sup>b</sup> , such as <i>Staphylococcus aureus</i> , <i>Streptococcus</i> spp.
Pigs	<i>Actinobacillus pleuropneumoniae</i>	<i>Escherichia coli</i> , <i>Salmonella</i> spp.	<i>Streptococcus suis</i>
Poultry	–	<i>Salmonella</i> spp.	<i>Escherichia coli</i>

<sup>a</sup>Adapted from information in reference 33.

<sup>b</sup>Refers to pathogens causing mastitis (mammary gland infection).

**Table 8.** Foodborne and indicator bacteria to include in an AMR monitoring programme

- In terrestrial food-producing animals, zoonotic bacteria typically include *Salmonella* spp. and *Campylobacter* spp. from caecal samples
- In terrestrial food-producing animals, indicator bacteria (animal commensal bacteria as potential reservoir of drug resistance genes) typically include *Escherichia coli* and enterococci from caecal samples
- Other bacteria (e.g. methicillin-resistant *Staphylococcus aureus*, *Clostridioides* spp. and *Listeria monocytogenes* from terrestrial food-producing animals or *Vibrio parahaemolyticus* and *Salmonella* spp. from aquaculture production) may be included according to the epidemiology of foodborne diseases in the area

activities in the One Health approach. The initial step of the literature review was useful in guiding group discussions and finding agreement. However, the subjective nature of the experts' opinions and the small number of participants remain limitations of the approach.

A major strength of this document is that it provides practical and concise indications for AMS teams in the field, but also for institutions wishing to support AMS from a higher level, especially when it relates to the production of AMR and AMU data that are relevant for prescribers, sellers and users of antimicrobials in animals. These indications are also useful for medical doctors wishing to better understand the specificities of the veterinary sector in terms of surveillance and AMS, especially as some activities are designed with a public health perspective. This work also enabled

the identification of several important future research areas to facilitate the development of AMS programmes and the translation of AMR surveillance data into prudent use of antimicrobials in the veterinary setting. However, due to the diversity and complexity of the veterinary sector, along with the fact that diverse economic contexts were considered, many targets of the checklist are rather generic and need to be adapted to each specific context. In this scenario, the indications given herein represent a first step to better structure AMS activities in the animal sector.

### Conclusions

A list of essential and desirable targets was produced following development of consensus between experts from both medical and

**Table 9.** Research priorities

- **Develop guidance on the specific tasks of AMS programmes, including staff requirement and time allocation per task, in different veterinary contexts.**

Rationale

Definition of roles and accountability is a prerequisite for any AMS programme. Compared with human medicine, the veterinary sector shows greater variability in animal species, animal populations (food-producing animals including aquaculture and companion animals) and the various contexts where animal healthcare is provided (farms, small veterinary clinics, large hospitals, etc.). Although planning dedicated time and allocating specific measures for AMS teams are essential for AMS activities, detailed information on the minimum requirements for personnel according to tasks of AMS programmes are not available in the literature. In this scenario, appropriate and detailed guidance on staff requirement and time to be allocated per specific task of AMS programmes, and tailored to the different veterinary contexts, represents a fundamental measure to foster AMS activities.

- **Produce missing veterinary clinical breakpoints.**

Rationale

A specific challenge that applies to the translation of AMR surveillance data into AMS activities in the veterinary setting is the lack of clinical breakpoints to interpret AST results for many combinations of animal species/bacterial species/clinical condition. When no breakpoint is available, epidemiological cut-offs (ECOFFs) can be used as an alternative. However, ECOFFs detect decreased susceptibilities and, as such, are not proper indicators of clinical resistance. When using ECOFFs instead of clinical breakpoints, resistance rates can be overestimated, so one should be cautious when providing treatment recommendations based on them.

- **Provide indications for the selective reporting of AST results to veterinarians.**

Rationale

The use of selective reporting is an important measure to optimize animal care and foster AMS. Reporting drugs that are typically effective against the pathogen and which are recommended for first-line regimens aids the veterinary clinicians in the appropriate use of antimicrobial agents, discouraging the unnecessary use of broad-spectrum agents. However, criteria for selective reporting in the animal sector have not been clearly defined.

- **Provide indications about resistance thresholds to translate AMR data into empirical therapy and surgical prophylaxis.**

Rationale

There are currently no indications regarding if and how resistance thresholds should be defined as part of AMS programmes to guide empirical therapy and prophylaxis. Studies forecasting reproducible models to support the determination of an antimicrobial-specific threshold (i.e. baseline resistance rate beyond which an antimicrobial must not be used) and exploring treatment outcomes of a threshold-driven switch in antimicrobial choices are fundamentally needed to ascertain and establish the role of resistance thresholds as criteria for decision support on choice of antimicrobials.

veterinary backgrounds. The proposed indications, which consider the connection with human medicine and the heterogeneity of the veterinary setting, aim to facilitate the development of AMS programmes linked to AMU and AMR surveillance data in the animal sector, but with benefits for both animal and human health. This White Paper, together with those produced in the hospital, outpatient and long-term care facility settings, provides the opportunity to compare practices and learn from other areas.

This series of White Papers represents a practical example of how the One Health approach can be useful in understanding priorities, capacities and needs among sectors. This overall initiative facilitates collaboration between all actors in animal and human health who are involved in AMS activities. This series also enabled the identification of relevant areas to engage for future research in order to facilitate the development of AMS programmes and the translation of surveillance data into prudent use of antimicrobials in the human and animal sectors.

## Acknowledgements

We are very grateful to Ruth Joanna Davis for her support in the management of the project, and to Michaela Hardiman and Nadine Conzelmann for their administrative support.

## Members of the ARCH working group

Ayola Akim Adegnikia, Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon and Institut für Tropenmedizin and German Center for Infection Research, partner site Tübingen, Universitätsklinikum, Wilhelmstraße, Tübingen, Germany; Fabiana Arieti, Infectious Diseases Section, Department of Diagnostics and Public Health, University of Verona, Verona, Italy; Nithya Babu Rajendran, Infectious Diseases, Department of Internal Medicine I, Tübingen University Hospital, Tübingen, Germany and German Centre for Infection Research (DZIF), Clinical Research Unit for healthcare associated infections, Tübingen, Germany; Julia Bielicki, Pediatric Infectious Diseases, University Children's Hospital Basel, Basel, Switzerland and Pediatric

Infectious Disease Research Group, Institute for Infection and Immunity, St George's University of London, London, UK; Steffen Borrmann, Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon and Institut für Tropenmedizin and German Center for Infection Research, partner site Tübingen, Universitätsklinikum, Wilhelmstraße, Tübingen, Germany; Elena Carrara, Infectious Diseases Section, Department of Diagnostics and Public Health, University of Verona, Verona, Italy; Roberto Cauda, Institute of Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy; Monica Compri, Infectious Diseases Section, Department of Diagnostics and Public Health, University of Verona, Verona, Italy; Giulia De Angelis, Dipartimento di Scienze Biotechnologiche di base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy and Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy; Maria-Eleni Filippitzi, Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium; Isabel Frost, Centre for Disease Dynamics, Economics & Policy, New Delhi, India and Faculty of Medicine, Department of Infectious Disease, Imperial College, London, UK; Liliana Galia, Infectious Diseases Section, Department of Diagnostics and Public Health, University of Verona, Verona, Italy; Petra Gastmeier, German Centre for Infection Research Association (DZIF), Braunschweig, Germany and Institute for Hygiene and Environmental Medicine, Charité - Universitätsmedizin Berlin, Germany, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Christian Giske, Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden and Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden; Siri Göpel, Infectious Diseases, Department of Internal Medicine I, Tübingen University Hospital, Tübingen, Germany and German Centre for Infection Research (DZIF), Clinical Research Unit for healthcare associated infections, Tübingen, Germany; Luca Guardabassi, Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark and Department of Pathobiology and Population Sciences, The Royal Veterinary College, Hatfield, UK; Annet Heuvelink, Royal GD, Deventer, The Netherlands; Jobke van Hout, Royal GD, Deventer, The Netherlands; Gunnar Kahlmeter, Department of Clinical Microbiology, Växjö Central Hospital, Växjö, Sweden; Souha S. Kanj, Division of Infectious Diseases, Department of Internal Medicine, and Infection Control and Prevention Program, and Antimicrobial Stewardship Program, American University of Beirut Medical Center, Beirut, Lebanon; Tomislav Kostyanov, Department of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium; Leonard Leibovici, Medicine E, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel and Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Jean-Christophe Lucet, Infection Control Unit, Bichat-Claude Bernard Hospital, AP-HP, Paris, France and IAME, UMR 1137, DeSCID team, Université Paris Diderot, Sorbonne Paris Cité, Paris, France; Lorena López-Cerero, Microbiology and Infectious Diseases Unit, University Hospital Virgen Macarena, Sevilla, Spain; Rodolphe Mader, University of Lyon, French Agency for Food, Environmental and Occupational Health and Safety (ANSES), Laboratory of Lyon, Antimicrobial Resistance and Bacterial Virulence Unit, Lyon, France; Fulvia Mazzaferri, Infectious Diseases Section, Department of Diagnostics and Public Health, University of Verona, Verona, Italy; Elena Mazzolini, Department of Epidemiology, Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro, Padua, Italy; Marc Mendelson, Division of Infectious Diseases and HIV Medicine, Department of Medicine, University of Cape Town, Cape Town, South Africa; Rita Murri, Institute of Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy; Nico T. Mutters, Institute for Hygiene and Public Health, Bonn University Hospital, Bonn, Germany; Mical Paul, Diseases Institute, Rambam Health Care Campus, Ruth and Bruce Rappaport Faculty of

Medicine, Technion - Israel Institute of Technology, Haifa, Israel; Maria Diletta Pezzani, Infectious Diseases Section, Department of Diagnostics and Public Health, University of Verona, Verona, Italy; Elisabeth Presterl, European Committee on Infection Control, Basel, Switzerland and Department of Infection Control and Hospital Epidemiology, Medical University of Vienna, Vienna, Austria; Hanna Renk, University Children's Hospital Tübingen, Department of Paediatric Cardiology, Pulmology and Intensive Care Medicine, Tübingen, Germany; Le Huu Song, Vietnamese German Center for Medical Research, Hanoi, Vietnam and 108 Military Central Hospital, Hanoi, Vietnam; Maurizio Sanguinetti, Dipartimento di Scienze Biotechnologiche di base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy and Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Remco Schrijver, VetEffect, Bilthoven, The Netherlands; Luigia Scudeller, Scientific Direction of IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy; Mike Sharland, Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George's University of London, London, UK; Marcella Sibani, Infectious Diseases Section, Department of Diagnostics and Public Health, University of Verona, Verona, Italy; Evelina Tacconelli, Infectious Diseases Section, Department of Diagnostics and Public Health, University of Verona, Verona, Italy and Infectious Diseases, Department of Internal Medicine I, Tübingen University Hospital, Tübingen, Germany and German Centre for Infection Research (DZIF), Clinical Research Unit for healthcare associated infections, Tübingen, Germany; Didem Torumkuney, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Geneva, Switzerland; Thirumalaisamy P. Velavan, Institute of Tropical Medicine, Universitätsklinikum Tübingen, Germany and Vietnamese German Center for Medical Research, Hanoi, Vietnam and Faculty of Medicine, Duy Tan University, Da Nang, Vietnam; Andreas Voss, Department of Medical Microbiology, Radboud University Medical Centre, Nijmegen, The Netherlands.

## Funding

This research project has received funding from the Innovative Medicines Initiative Joint Undertaking under grant agreement No 115737, resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and European Federation of Pharmaceutical Industries and Federations (EFPIA) companies in-kind contribution, and the German Federal Ministry of Education and Research (BMBF) [Project ID 01KI1830] under the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) 2018 call.

The contribution of Rodolphe Mader, as a member of the European Antimicrobial Resistance Surveillance network in Veterinary medicine (EARS-Vet), has been co-funded by the 3rd Health Programme of the European Union (2014–2020) under the European Union Joint Action on Antimicrobial Resistance and Healthcare Associated Infections (EU-JAMRAI) [grant agreement No 761296].

## Transparency declarations

All authors: none to declare. Patrick Moore of Adriatic Health Communications provided medical writing services for the editing and proofing of this paper. This article forms part of a Supplement.

## References

- 1 World Health Organization. *WHO Guidelines on Use of Medically Important Antimicrobials in Food-Producing Animals*. [https://www.who.int/foodsafety/publications/cia\\_guidelines/en/](https://www.who.int/foodsafety/publications/cia_guidelines/en/).

- 2 McEwen SA, Collignon PJ. Antimicrobial resistance: a One Health perspective. *Microbiol Spectr* 2018; **6**: doi:10.1128/microbiolspec.ARBA-0009-2017.
- 3 Prescott JF. History and current use of antimicrobial drugs in veterinary medicine. *Microbiol Spectr* 2017; **5**: doi:10.1128/microbiolspec.ARBA-0002-2017.
- 4 Lloyd DH, Page SW. Antimicrobial stewardship in veterinary medicine. *Microbiol Spectr* 2018; **6**: doi:10.1128/microbiolspec.ARBA-0023-2017.
- 5 Collignon PJ, McEwen SA. One Health—its importance in helping to better control antimicrobial resistance. *Trop Med Infect Dis* 2019; **4**: 22.
- 6 Robinson TP, Bu DP, Carrique-Mas J *et al*. Antibiotic resistance is the quintessential One Health issue. *Trans R Soc Trop Med Hyg* 2016; **110**: 377–80.
- 7 Dyar OJ, Huttner B, Schouten J *et al*. What is antimicrobial stewardship? *Clin Microbiol Infect* 2017; **23**: 793–8.
- 8 European Food Safety Authority. *Manual for Reporting on Antimicrobial Resistance within the Framework of Directive 2003/99/EC and Decision 2013/652/EU for Information Derived from the Year 2017*. <https://efsa.onlinelibrary.wiley.com/doi/pdf/10.2903/sp.efsa.2018.EN-1370>.
- 9 European Medicines Agency. *Categorisation of Antibiotics in the European Union. Answer to the Request from the European Commission for Updating the Scientific Advice on the Impact on Public Health and Animal Health of the Use of Antibiotics in Animals*. [https://www.ema.europa.eu/en/documents/report/categorisation-antibiotics-european-union-answer-request-european-commission-updating-scientific\\_en.pdf](https://www.ema.europa.eu/en/documents/report/categorisation-antibiotics-european-union-answer-request-european-commission-updating-scientific_en.pdf).
- 10 American Association of Bovine Practitioners. *AABP Guidelines: Key Elements for Implementing Antimicrobial Stewardship Plans in Bovine Veterinary Practices Working with Beef and Dairy Operations*. [http://aabp.org/resources/AABP\\_Guidelines/AntimicrobialStewardship-7.27.17.pdf](http://aabp.org/resources/AABP_Guidelines/AntimicrobialStewardship-7.27.17.pdf).
- 11 Animal Health Australia. *Antimicrobial Stewardship in Australian Livestock Industries 2018*. <https://www.animalhealthaustralia.com.au/antimicrobial-stewardship-in-australian-livestock-industries/>.
- 12 American Veterinary Medical Association. *Task Force on Antimicrobial Stewardship in Companion Animal Practice: Activities August 2013–December 2015*. [www.avma.org/KB/Resources/Reports/Documents/TFASCAP\\_Report.pdf](http://www.avma.org/KB/Resources/Reports/Documents/TFASCAP_Report.pdf).
- 13 Frey E. The role of companion animal veterinarians in One-Health efforts to combat antimicrobial resistance. *J Am Vet Med Assoc* 2018; **253**: 1396–404.
- 14 Guardabassi L. Antimicrobial resistance: a global threat with remarkable geographical differences. *N Z Vet J* 2017; **65**: 57–9.
- 15 Official Journal of the European Union. *Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on Veterinary Medicinal Products and Repealing Directive 2001/82/EC*. <https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32019R0006&from=EN>.
- 16 American Veterinary Medical Association. *Judicious Therapeutic Use of Antimicrobials*. <https://www.avma.org/policies/judicious-therapeutic-use-antimicrobials>.
- 17 World Organisation for Animal Health. *OIE Annual Report on Antimicrobial Agents Intended for Use in Animals. 3rd Report. Paris, France: OIE, 2018*. [https://www.oie.int/fileadmin/Home/eng/Our\\_scientific\\_expertise/docs/pdf/AMR/Annual\\_Report\\_AMR\\_3.pdf](https://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/AMR/Annual_Report_AMR_3.pdf).
- 18 Guardabassi L, Apley M, Olsen JE *et al*. Optimization of antimicrobial treatment to minimize resistance selection. *Microbiol Spectr* 2018; **6**: doi:10.1128/microbiolspec.ARBA-0018-2017.
- 19 Prescott JF. Veterinary antimicrobial stewardship in North America. *Aust Vet J* 2019; **97**: 243–8.
- 20 Schellack N, Benjamin D, Brink A *et al*. A situational analysis of current antimicrobial governance, regulation, and utilization in South Africa. *Int J Infect Dis* 2017; **64**: 100–6.
- 21 Chauhan AS, George MS, Chatterjee P *et al*. The social biography of antibiotic use in smallholder dairy farms in India. *Antimicrob Resist Infect Control* 2018; **7**: 60.
- 22 Eagar H, Naidoo V. Veterinary antimicrobial stewardship in South Africa. *Int Biol Rev* 2017; **1**: doi:10.18103/ibr.v1i2.1367.
- 23 Manishimwe R, Nishimwe K, Ojok L. Assessment of antibiotic use in farm animals in Rwanda. *Trop Anim Health Prod* 2017; **49**: 1101–6.
- 24 DANMAP. *Use of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Bacteria from Food Animals, Food and Humans in Denmark*. <https://www.danmap.org/-/media/arkiv/projekt-sites/danmap/danmap-reports/danmap-2017/danmap2017.pdf>.
- 25 Magouras I, Carmo LP, Stark KDC *et al*. Antimicrobial usage and -resistance in livestock: where should we focus? *Front Vet Sci* 2017; **4**: 148.
- 26 Werner N, McEwen S, Kreienbrock L. Monitoring antimicrobial drug usage in animals: methods and applications. *Microbiol Spectr* 2018; **6**: doi:10.1128/microbiolspec.ARBA-0015-2017.
- 27 European Medicines Agency. *Guidance on Collection and Provision of National Data on Antimicrobial Use by Animal Species/Categories*. Amsterdam, Netherlands: EMA, 2018. [https://www.ema.europa.eu/en/documents/scientific-guideline/guidance-collection-provision-national-data-antimicrobial-use-animal-species/categories\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/guidance-collection-provision-national-data-antimicrobial-use-animal-species/categories_en.pdf).
- 28 Mills HL, Turner A, Morgans L *et al*. Evaluation of metrics for benchmarking antimicrobial use in the UK dairy industry. *Vet Rec* 2018; **182**: 379.
- 29 Pinto FJ. Why antibiotic use data in animals needs to be collected and how this can be facilitated. *Front Vet Sci* 2017; **4**: 213.
- 30 Tanaka N, Takizawa T, Miyamoto N *et al*. Real world data of a veterinary teaching hospital in Japan: a pilot survey of prescribed medicines. *Vet Rec Open* 2017; **4**: e000218.
- 31 Danish Veterinary and Food Administration. *Special Provisions for the Reduction of the Consumption of Antibiotics in Pig Holdings (The Yellow Card Initiative)*. DVFA, 2013. <https://www.foedevarestyrelsen.dk/english/SiteCollectionDocuments/Dyrevelvfaerd%20og%20veterinaermedicin/Veterin%C3%A6rmedicin/Yellow%20Card,%20English%20version,%20180517.pdf>.
- 32 Padiyara P, Inoue H, Sprenger M. Global governance mechanisms to address antimicrobial resistance. *Infect Dis (Auckl)* 2018; **11**: 11786337 18767887.
- 33 World Organisation for Animal Health. *Harmonisation of national antimicrobial resistance surveillance and monitoring programmes*. In: *Terrestrial Animal Health Code Chapter 6.8*. Paris, France: OIE, 2019. [https://www.oie.int/fileadmin/Home/eng/Health\\_standards/tahc/current/chapitre\\_antibio\\_harmonisation.pdf](https://www.oie.int/fileadmin/Home/eng/Health_standards/tahc/current/chapitre_antibio_harmonisation.pdf).
- 34 Burns T, Radke BR, Stitt T *et al*. Developing an evidence-based approach for antimicrobial resistance reporting for British Columbia diagnostic animal health laboratory data. *Can Vet J* 2018; **59**: 480–90.
- 35 Ceric O, Tyson GH, Goodman LB *et al*. Enhancing the One Health initiative by using whole genome sequencing to monitor antimicrobial resistance of animal pathogens: Vet-LIRN collaborative project with veterinary diagnostic laboratories in United States and Canada. *BMC Vet Res* 2019; **15**: 130.
- 36 World Health Organization. *Integrated Surveillance of Antimicrobial Resistance in Foodborne Bacteria: Application of a One Health Approach*. <https://apps.who.int/iris/bitstream/handle/10665/255747/9789241512411-eng.pdf>.
- 37 European Food Safety Authority. *The European Union Summary Report on Antimicrobial Resistance in Zoonotic and Indicator Bacteria from Humans, Animals and Food in 2017*. <https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2019.5598>.
- 38 Karp BE, Tate H, Plumlee JR *et al*. National antimicrobial resistance monitoring system: two decades of advancing public health through integrated surveillance of antimicrobial resistance. *Foodborne Pathog Dis* 2017; **14**: 545–57.
- 39 Public Health Agency of Canada. *Tackling Antimicrobial Resistance and Antimicrobial Use. A Pan-Canadian Framework for Action*. <https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/tackling-antimicrobial-resistance-use-pan-canadian-framework-action.html>.

- 40** Ferreira JP, Staerk K. Antimicrobial resistance and antimicrobial use animal monitoring policies in Europe: where are we? *J Public Health Policy* 2017; **38**: 185–202.
- 41** Hopman NEM, van Dijk MAM, Broens EM et al. Quantifying antimicrobial use in Dutch companion animals. *Front Vet Sci* 2019; **6**:158.
- 42** Yevutsey SK, Buabeng KO, Aikins M et al. Situational analysis of antibiotic use and resistance in Ghana: policy and regulation. *BMC Public Health* 2017; **17**: 896.
- 43** Public Health Agency of Sweden and National Veterinary Institute. *SWEDRES-SVARM Consumption of Antibiotics and Occurrence of Antibiotic Resistance in Sweden*. 2018. [https://www.sva.se/media/k3mnhqbs/swedres\\_svarm2018.pdf](https://www.sva.se/media/k3mnhqbs/swedres_svarm2018.pdf).
- 44** AMR One Health Surveillance Committee. *Nippon AMR One Health Report (NAOR)*. 2017. <https://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000204347.pdf>.
- 45** Schrijver R, Stijntjes M, Rodriguez-Bano J et al. Review of antimicrobial resistance surveillance programmes in livestock and meat in EU with focus on humans. *Clin Microbiol Infect* 2018; **24**: 577–90.
- 46** Simjee S, McDermott P, Trott DJ et al. Present and future surveillance of antimicrobial resistance in animals: principles and practices. *Microbiol Spectr* 2018; **6**: doi:10.1128/microbiolspec.ARBA-0028-2017.
- 47** Smith P, Alday-Sanz V, Matysczak J et al. Monitoring and surveillance of antimicrobial resistance in microorganisms associated with aquatic animals. *Rev Sci Tech* 2013; **32**: 583–93.
- 48** Interagency Coordination Group. *Surveillance and Monitoring for Antimicrobial Use and Resistance*. [https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG\\_Surveillance\\_and\\_Monitoring\\_for\\_AMU\\_and\\_AMR\\_110618.pdf](https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG_Surveillance_and_Monitoring_for_AMU_and_AMR_110618.pdf).
- 49** Goutard FL, Bordier M, Calba C et al. Antimicrobial policy interventions in food animal production in South East Asia. *BMJ* 2017; **358**: j3544.
- 50** JPIAMR ARCH. <https://archnet-surveillance.eu/>.
- 51** COMBACTE-MAGNET EPI-Net. <https://epi-net.eu/>.
- 52** Pezzani MD, Carrara E, Sibani M et al. White Paper: Bridging the gap between human and animal surveillance data, antibiotic policy and stewardship in the hospital sector—practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks. *J Antimicrob Chemother* 2020; **75** Suppl 2: ii20–ii32.
- 53** Pezzani MD, Mazzaferri F, Compri M et al. Linking antimicrobial resistance surveillance to antibiotic policy in healthcare settings: the COMBACTE-Magnet EPI-Net COACH project. *J Antimicrob Chemother* 2020; **75** Suppl 2: ii2–ii19.
- 54** The University of Melbourne. *Australian Veterinary Prescribing Guidelines/ Antimicrobial stewardship. Veterinary Antimicrobial Stewardship Program*. <https://vetantibiotics.fvas.unimelb.edu.au/about/antimicrobial-stewardship/>.
- 55** Official Journal of the European Union. *Commission Notice. Guidelines for the Prudent Use of Antimicrobials in Veterinary Medicine (2015/C 299/04)*. 2015. [https://ec.europa.eu/health/sites/health/files/antimicrobial\\_resistance/docs/2015\\_prudent\\_use\\_guidelines\\_en.pdf](https://ec.europa.eu/health/sites/health/files/antimicrobial_resistance/docs/2015_prudent_use_guidelines_en.pdf).
- 56** British Veterinary Association. *BVA Policy Position on the Responsible Use of Antimicrobials in Food Producing Animals*. <https://www.bva.co.uk/media/1161/bva-policy-position-on-the-responsible-use-of-antimicrobials-in-food-producing-animals-1.pdf>.
- 57** Norwegian livestock industry. *The Norwegian Livestock Industry's Joint Action Plan on Antimicrobial Resistance*. [https://www.animalia.no/contentasets/0feb9d19eb4b47338d704b18529ad253/eng\\_husdyrnaringas-hplan-amr-enderalig-enkeltstider\\_220617.pdf](https://www.animalia.no/contentasets/0feb9d19eb4b47338d704b18529ad253/eng_husdyrnaringas-hplan-amr-enderalig-enkeltstider_220617.pdf).
- 58** Food and Drug Administration Center for Veterinary Medicine. *Supporting Antimicrobial Stewardship in Veterinary Settings: Goals for Fiscal Years 2019–2023*. <https://www.fda.gov/downloads/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/UCM620420.pdf>.
- 59** Food and Agriculture Organization. *Antimicrobial Resistance Policy Review and Development Framework—A Regional Guide for Governments in Asia and the Pacific to Review, Update and Develop Policy to Address Antimicrobial Resistance and Antimicrobial Use in Animal Production*. <http://www.fao.org/3/CA1486EN/ca1486en.pdf>.
- 60** European Commission. Directorate-General for Health and Food Safety. *Measures to Tackle Antimicrobial Resistance through the Prudent Use of Antimicrobials in Animals. European Commission. Overview Report*. <https://op.europa.eu/en/publication-detail/-/publication/aa676ddd-2d87-11e8-b5fe-01aa75ed71a1/language-en/format-PDF/source-search>.
- 61** Responsible Use of Medicines in Agriculture (RUMA) Alliance. *Targets Task Force Report 2017*. <https://www.ruma.org.uk/wp-content/uploads/2017/10/RUMA-Targets-Task-Force-Report-2017-FINAL.pdf>.
- 62** AACTING-Network. *Guidelines for Collection, Analysis and Reporting of Farm Level Antimicrobial Use, in the Scope of Antimicrobial Stewardship*. [https://aacting.org/swfiles/files/AACTING\\_Guidelines\\_V1.1\\_2018.03.23\\_39.pdf](https://aacting.org/swfiles/files/AACTING_Guidelines_V1.1_2018.03.23_39.pdf).
- 63** Finnish Food Safety Authority. *Recommendations for the Use of Antimicrobials in the Treatment of the Most Significant Infectious and Contagious Diseases in Animals*. [https://www.ruokavirasto.fi/globalassets/vilje/lijat/elaintenpito/elainten-laokitsemisen/hallittu\\_laakekaytto/mikrobilaakke\\_kaytonperiaatteet/mikrobilaakkeiden\\_kayttosuositukset\\_en.pdf](https://www.ruokavirasto.fi/globalassets/vilje/lijat/elaintenpito/elainten-laokitsemisen/hallittu_laakekaytto/mikrobilaakke_kaytonperiaatteet/mikrobilaakkeiden_kayttosuositukset_en.pdf).
- 64** World Organisation for Animal Health. *Guidance for Completing the OIE Template for the Collection of Data Antimicrobial Agents Intended for Use in Animals*. [https://www.oie.int/fileadmin/Home/eng/Our\\_scientific\\_expertise/docs/pdf/AMR/A\\_AMUse\\_Final\\_Guidance\\_2017.pdf](https://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/AMR/A_AMUse_Final_Guidance_2017.pdf).
- 65** European Medicine Agency. *Sales of Veterinary Antimicrobial Agents in 30 European Countries in 2016. Trends from 2010 to 2016*. Eighth ESVAC Report. [https://www.ema.europa.eu/en/documents/report/sales-veterinary-antimicrobial-agents-30-european-countries-2016-trends-2010-2016-eighth-esvac\\_en.pdf](https://www.ema.europa.eu/en/documents/report/sales-veterinary-antimicrobial-agents-30-european-countries-2016-trends-2010-2016-eighth-esvac_en.pdf).
- 66** Food and Drug Administration. *Summary Report on Antimicrobials Sold or Distributed for Use in Food-Producing Animals*. <https://www.fda.gov/media/133411/download>.
- 67** World Organisation for Animal Health. Development and harmonisation of national antimicrobial resistance surveillance and monitoring programmes for aquatic animals. In: *Aquatic Animal Health Code Chapter 6.4*. Paris, France: OIE, 2018. [https://www.oie.int/fileadmin/Home/eng/Health\\_standards/aahc/current/chapitre\\_antibio\\_development\\_harmonisation.pdf](https://www.oie.int/fileadmin/Home/eng/Health_standards/aahc/current/chapitre_antibio_development_harmonisation.pdf).
- 68** Ashley EA, Recht J, Chua A et al. *Antimicrobial Resistance in Low and Middle Income Countries. An Analysis of Surveillance Networks*. [https://www.iddo.org/sites/default/files/publication/2018-04/fleming\\_scoping\\_amr\\_net\\_works\\_0.pdf](https://www.iddo.org/sites/default/files/publication/2018-04/fleming_scoping_amr_net_works_0.pdf).
- 69** World Organisation for Animal Health. *Laboratory Methodologies for Bacterial Antimicrobial Susceptibility Testing*. [https://www.oie.int/fileadmin/Home/eng/Our\\_scientific\\_expertise/docs/pdf/GUIDE\\_2.1\\_ANTIMICROBIAL.pdf](https://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/GUIDE_2.1_ANTIMICROBIAL.pdf).
- 70** British Veterinary Association. *Responsible Use of Antimicrobials in Veterinary Practice*. <https://www.bva.co.uk/news-campaigns-and-policy/policy/medicines/antimicrobials/>.
- 71** American Veterinary Medical Association. *Antimicrobial Stewardship Definition and Core Principles*. <https://www.avma.org/KB/Policies/Pages/Antimicrobial-Stewardship-Definition-and-Core-Principles.aspx>.
- 72** American Veterinary Medical Association. *Judicious Therapeutic Use of Antimicrobials in Aquatic Animal Medicine*. <https://www.avma.org/KB/Policies/Pages/Judicious-Use-of-Antimicrobials-for-Treatment-of-Aquatic-Animals-by-Veterinarians.aspx>.
- 73** American Association of Avian Pathologists—American Veterinary Medical Association. *AAAP/AVMA Guidelines for Judicious Therapeutic Use of Antimicrobials in Poultry*. <https://www.avma.org/KB/Policies/Pages/AAAP-Guidelines-to-Judicious-Therapeutic-Use-of-Antimicrobials-in-Poultry.aspx>.

- 74** National Aquaculture Association. *Judicious Antimicrobial Use in US Aquaculture: Principles and Practices*. [https://www.caaquaculture.org/wp-content/uploads/2017/05/NAA-White-Paper-Judicious-Antimicrobial-Use-in-US-Aquaculture-Principles-and-Practices-03\\_03.pdf](https://www.caaquaculture.org/wp-content/uploads/2017/05/NAA-White-Paper-Judicious-Antimicrobial-Use-in-US-Aquaculture-Principles-and-Practices-03_03.pdf).
- 75** Food and Drug Administration. *FDA's Proposed Method for Adjusting Data on Antimicrobials Sold or Distributed for Use in Food-Producing Animals, Using a Biomass Denominator*. <https://www.fda.gov/files/animal%20&%20veterinary/published/FDA%E2%80%99s-Proposed-Method-for-Adjusting-Data-on-Antimicrobials-Sold-or-Distributed-for-Use-in-Food-Producing-Animals-Using-a-Biomass-Denominator-Technical-Paper.pdf>.
- 76** The University of Melbourne. *Antimicrobial Stewardship*. <https://vetantibiotics.fvas.unimelb.edu.au/about/antimicrobial-stewardship/>.
- 77** New Zealand Veterinary Association. *Antibiotic Judicious Use Guidelines for the New Zealand Veterinary Profession*. [https://cdn.ymaws.com/www.nzva.org.nz/resource/resmgr/docs/policies\\_and\\_guidelines/guide\\_equine.pdf](https://cdn.ymaws.com/www.nzva.org.nz/resource/resmgr/docs/policies_and_guidelines/guide_equine.pdf).
- 78** NORM/NORM-VET 2017. *Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway*. [https://lunn.no/Documents/Kompetansetjenester,%20-sentre%20og%20fagråd/NORM%20-%20Norsk%20overvåkingsystem%20for%20antibiotikaresistens%20hos%20mikrober/Rapporter/NORM\\_NORM-VET\\_2017.pdf](https://lunn.no/Documents/Kompetansetjenester,%20-sentre%20og%20fagråd/NORM%20-%20Norsk%20overvåkingsystem%20for%20antibiotikaresistens%20hos%20mikrober/Rapporter/NORM_NORM-VET_2017.pdf).
- 79** Swedish Veterinary Association. *Guidelines for the Clinical Use of Antibiotics in the Treatment of Dogs and Cats*. <https://www.svf.se/media/ahwpbt52/policy-ab-english-10b.pdf>.
- 80** British Small Animal Veterinary Association. *BSAVA Guide to the Use of Veterinary Medicines*. <https://www.bsavalibrary.com/content/book/10.22233/9781905319862>.
- 81** British Small Animal Veterinary Association and Small Animal Medicine Society. *Guide to Responsible Use of Antibacterials: PROTECT ME*. <https://www.bsavalibrary.com/content/book/10.22233/9781910443644>.
- 82** European Medicines Agency. *Updated Advice on the Use of Colistin Products in Animals within the European Union: Development of Resistance and Possible Impact on Human and Animal Health*. [https://www.ema.europa.eu/en/documents/scientific-guideline/updated-advice-use-colistin-products-animals-within-european-union-development-resistance-possible\\_en-0.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/updated-advice-use-colistin-products-animals-within-european-union-development-resistance-possible_en-0.pdf).
- 83** European Medicines Agency. *Principles on Assignment of Defined Daily Dose for Animals (DDDvet) and Defined Course Dose for Animals (DCDvet)*. [https://www.ema.europa.eu/en/documents/scientific-guideline/principles-assignment-defined-daily-dose-animals-dddvet-defined-course-dose-animals-dcdvet\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/principles-assignment-defined-daily-dose-animals-dddvet-defined-course-dose-animals-dcdvet_en.pdf).
- 84** European Centre for Disease Prevention and Control—European Food Safety Authority—European Medicines Agency. *ECDC, EFSA and EMA Joint Scientific Opinion on a List of Outcome Indicators as Regards Surveillance of Antimicrobial Resistance and Antimicrobial Consumption in Humans and Food-Producing Animals*. <https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2017.5017>.
- 85** World Organisation for Animal Health. *Monitoring of the Quantities and Usage Patterns of Antimicrobial Agents Used in Food Producing Animals*. [https://www.oie.int/fileadmin/Home/eng/Health\\_standards/tahc/current/chapitre\\_antibio\\_monitoring.pdf](https://www.oie.int/fileadmin/Home/eng/Health_standards/tahc/current/chapitre_antibio_monitoring.pdf).
- 86** World Organisation for Animal Health. *Monitoring of the Quantities and Usage Patterns of Antimicrobial Agents Used in Aquatic Animals*. [https://www.oie.int/fileadmin/Home/eng/Health\\_standards/aahc/current/chapitre\\_antibio\\_quantities\\_usage\\_patterns.pdf](https://www.oie.int/fileadmin/Home/eng/Health_standards/aahc/current/chapitre_antibio_quantities_usage_patterns.pdf).
- 87** Minnesota Department of Health. *VMC Antibigram*. <https://www.health.state.mn.us/diseases/antibioticresistance/animal/vmcantibiogram.pdf>.
- 88** Review on Antimicrobial Resistance. *Tackling Drug-Resistant Infections Globally: Final Report and Recommendations*. <https://amr-review.org/Publications.html>.
- 89** Cabello FC, Godfrey HP, Tomova A *et al*. Antimicrobial use in aquaculture re-examined: its relevance to antimicrobial resistance and to animal and human health. *Environ Microbiol* 2013; **15**: 1917–42.
- 90** Carrique-Mas JJ, Rushton J. Integrated interventions to tackle antimicrobial usage in animal production systems: the ViParc Project in Vietnam. *Front Microbiol* 2017; **8**: 1062.
- 91** Chuah LO, Effarizah ME, Goni AM *et al*. Antibiotic application and emergence of multiple antibiotic resistance (MAR) in global catfish aquaculture. *Curr Environ Health Res* 2016; **3**: 118–27.
- 92** Collineau L, Belloc C, Stark KD *et al*. Guidance on the selection of appropriate indicators for quantification of antimicrobial usage in humans and animals. *Zoonoses Public Health* 2017; **64**: 165–84.
- 93** Collineau L, Carmo LP, Endimiani A *et al*. Risk ranking of antimicrobial-resistant hazards found in meat in Switzerland. *Risk Anal* 2018; **38**: 1070–84.
- 94** Cuong NV, Padungtod P, Thwaites G *et al*. Antimicrobial usage in animal production: a review of the literature with a focus on low- and middle-income countries. *Antibiotics (Basel)* 2018; **7**: 75.
- 95** Dargatz DA, Erdman MM, Harris B. A survey of methods used for antimicrobial susceptibility testing in veterinary diagnostic laboratories in the United States. *J Vet Diagn Invest* 2017; **29**: 669–75.
- 96** Eagar H, Swan G, van Vuuren M. A survey of antimicrobial usage in animals in South Africa with specific reference to food animals. *J S Afr Vet Assoc* 2012; **83**: 16.
- 97** Founou LL, Amoako DG, Founou RC *et al*. Antibiotic resistance in food animals in Africa: a systematic review and meta-analysis. *Microb Drug Resist* 2018; **24**: 648–65.
- 98** Gay N, Belmonte O, Collard JM *et al*. Review of antibiotic resistance in the Indian Ocean Commission: a human and animal health issue. *Front Public Health* 2017; **5**: 162.
- 99** Gomez DE, Arroyo LG, Poljak Z *et al*. Implementation of an algorithm for selection of antimicrobial therapy for diarrhoeic calves: impact on antimicrobial treatment rates, health and faecal microbiota. *Vet J* 2017; **226**: 15–25.
- 100** Guardabassi L, Prescott JF. Antimicrobial stewardship in small animal veterinary practice: from theory to practice. *Vet Clin North Am Small Anim Pract* 2015; **45**: 361–76, vii.
- 101** Hardefeldt LY. Implementing antimicrobial stewardship programmes in veterinary practices. *Vet Rec* 2018; **182**: 688–90.
- 102** Hardefeldt LY, Gilkerson JR, Billman-Jacobe H *et al*. Barriers to and enablers of implementing antimicrobial stewardship programs in veterinary practices. *J Vet Intern Med* 2018; **32**: 1092–9.
- 103** Henriksson PJG, Rico A, Troell M *et al*. Unpacking factors influencing antimicrobial use in global aquaculture and their implication for management: a review from a systems perspective. *Sustain Sci* 2018; **13**: 1105–20.
- 104** Jordan D. Antimicrobial ratings: the importance of importance. *Aust Vet J* 2019; **97**: 283–4.
- 105** Kasabova S, Hartmann M, Werner N *et al*. Used daily dose vs. defined daily dose—contrasting two different methods to measure antibiotic consumption at the farm level. *Front Vet Sci* 2019; **6**: 116.
- 106** MacKinnon MC, Pearl DL, Carson CA *et al*. Comparison of annual and regional variation in multidrug resistance using various classification metrics for generic *Escherichia coli* isolated from chicken abattoir surveillance samples in Canada. *Prev Vet Med* 2018; **154**: 9–17.
- 107** Marques C, Gama LT, Belas A *et al*. European multicenter study on antimicrobial resistance in bacteria isolated from companion animal urinary tract infections. *BMC Vet Res* 2016; **12**: 213.
- 108** Miller RA, Harbottle H. Antimicrobial drug resistance in fish pathogens. *Microbiol Spectr* 2018; **6**: doi:10.1128/microbiolspec.ARBA-0017-2017.
- 109** Nhung NT, Cuong NV, Thwaites G *et al*. Antimicrobial usage and antimicrobial resistance in animal production in Southeast Asia: a review. *Antibiotics (Basel)* 2016; **5**: 37.
- 110** Otto SJG, Szkotnicki J, McElwain C *et al*. Building the antimicrobial stewardship leadership plan for animal health in Canada (workshop, Ottawa, October 3–4, 2017). *Can Vet J* 2018; **59**: 746–8.

- 111** Rendle DI, Page SW. Antimicrobial resistance in companion animals. *Equine Vet J* 2018; **50**: 147–52.
- 112** Schar D, Sommanustweechai A, Laxminarayan R et al. Surveillance of antimicrobial consumption in animal production sectors of low- and middle-income countries: optimizing use and addressing antimicrobial resistance. *PLoS Med* 2018; **15**: e1002521.
- 113** Sommanustweechai A, Tangcharoensathien V, Malathum K et al. Implementing national strategies on antimicrobial resistance in Thailand: potential challenges and solutions. *Public Health* 2018; **157**: 142–6.
- 114** Toutain PL, Bousquet-Melou A, Damborg P et al. En route towards European clinical breakpoints for veterinary antimicrobial susceptibility testing: a position paper explaining the VetCAST approach. *Front Microbiol* 2017; **8**: 2344.
- 115** Watts JL, Sweeney MT, Lubbers BV. Antimicrobial susceptibility testing of bacteria of veterinary origin. *Microbiol Spectr* 2018; **6**: doi:10.1128/microbiolspec.ARBA-0001-2017.
- 116** Weese JS, Giguere S, Guardabassi L et al. ACVIM consensus statement on therapeutic antimicrobial use in animals and antimicrobial resistance. *J Vet Intern Med* 2015; **29**: 487–98.
- 117** Weir M, Rajic A, Dutil L et al. Zoonotic bacteria, antimicrobial use and antimicrobial resistance in ornamental fish: a systematic review of the existing research and survey of aquaculture-allied professionals. *Epidemiol Infect* 2012; **140**: 192–206.
- 118** Lhermie G, Grohn YT, Raboisson D. Addressing antimicrobial resistance: an overview of priority actions to prevent suboptimal antimicrobial use in food-animal production. *Front Microbiol* 2016; **7**: 2114.
- 119** Essack SY, Desta AT, Abotsi RE et al. Antimicrobial resistance in the WHO African region: current status and roadmap for action. *J Public Health (Oxf)* 2017; **39**: 8–13.
- 120** Bourelly C, Chauvin C, Jouy E et al. Comparative epidemiology of *E. coli* resistance to third-generation cephalosporins in diseased food-producing animals. *Vet Microbiol* 2018; **223**: 72–8.
- 121** Agerso Y, Aarestrup FM. Voluntary ban on cephalosporin use in Danish pig production has effectively reduced extended-spectrum cephalosporinase-producing *Escherichia coli* in slaughter pigs. *J Antimicrob Chemother* 2013; **68**: 569–72.
- 122** Center for Disease Dynamics, Economics & Policy. *Antibiotic Use and Resistance in Food Animals—Current Policy and Recommendations*. [https://cddep.org/wp-content/uploads/2017/06/india\\_abx\\_report-2.pdf](https://cddep.org/wp-content/uploads/2017/06/india_abx_report-2.pdf).
- 123** World Organisation for Animal Health. *RESOLUTION No. 36. Combating Antimicrobial Resistance through a One Health Approach: Actions and OIE Strategy*. [http://www.oie.int/fileadmin/Home/eng/Our\\_scientific\\_expertise/docs/pdf/AMR/A\\_RESO\\_AMR\\_2016.pdf](http://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/AMR/A_RESO_AMR_2016.pdf).
- 124** Burgess BA, Morley PS. Veterinary hospital surveillance systems. *Vet Clin North Am Small Anim Pract* 2015; **45**: 235–42.
- 125** Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals*. 4th ed. <http://vet01s.edaptivedocs.info/Login.aspx?ga=2.195758828.1947079996.1583800668-1050607875.1516728494>.
- 126** Veterinary European Committee on Antimicrobial Susceptibility Testing. *Florfenicol: Rationale for the Clinical Breakpoints, Version Number 1.0, year 2019*. <http://www.eucast.org>.